Abstracts

The Impact of HAART CNS Penetration Effectiveness on Brain Integrity in HIV+ Adults

Background: Highly active antiretroviral therapy (HAART) reduces morbidity and mortality due to human immunodeficiency virus (HIV), however cognitive impairment continues to persist. It remains uncertain whether HAART regimens with a high degree of central nervous system penetration effectiveness (CPE) exert beneficial neurological outcomes in HIV-infected (HIV+) individuals on stable treatment. The present cross sectional study…

Quantitative Electroencephalogram as a Translational Biomarker for NNRTI CNS AEs

Background: Although it is an effective drug for treating HIV-1 infection, the non-nucleoside RT inhibitor (NNRTI) efavirenz (EFV) elicits significant CNS adverse events (AEs) such as insomnia, headache, nausea, dizziness, cognitive impairment and depression. Currently marketed NNRTIs vary in efficacy and have varying degrees of CNS AEs. Therefore, an NNRTI with high efficacy and low…

Neurocognitive Impairment in Diverse Resource-Limited Settings: The International Neurological Study ACTG A5199 and A5271

Background: While neurocognitive impairment in HIV remains prevalent despite potent antiretroviral therapy (ART), there is a lack of infrastructure for conducting neurological research in resource limited settings (RLS), including normative data needed for clinical interpretation. A5271 provided training of clinical site personnel and collected normative comparison data. Here we provide estimates of neurocognitive impairment in…

High Frequency of Dementia in Antiretroviral-Naïve HIV+ Individuals in Rural Uganda

Background: HIV dementia was seen in 31% of 81 antiretroviral (ARV) naïve HIV+ individuals in a previous study in Kampala, Uganda. The frequency and risk factors for each stage of HIV-associated neurocognitive disorder (HAND), i.e., asymptomatic neurocognitive disorder (ANI), mild neurocognitive disorder (MND), and HIV dementia (HAD), in rural Sub-Saharan Africa is largely unknown. The…

Validation of the International HIV Dementia Scale Screening Tool for HAND in Uganda

Background: HIV-associated neurocognitive disorders (HAND) are prevalent and often under-diagnosed complications of HIV. The International HIV Dementia Scale (IHDS) has been validated as a useful screening tool for HIV-associated dementia (HAD) in a number of settings, including Kampala, Uganda. However, little is known about the utility of the IHDS in rural sub-Saharan Africa. The objective…

Cerebrospinal Fluid Cytokines and HIV-Associated Neurocognitive Disorders in Uganda

Background: In antiretroviral (ARV) naïve HIV+ individuals and HIV subtype B infection in the US, HIV associated neurocognitive disorder (HAND) is associated with increased cerebrospinal fluid (CSF) inflammatory cytokines. To better understand the neurocognitive effects of HIV in Uganda where HIV subtypes D and A predominate, we compared the expression of varying cytokines and neurodegenerative…

A Comparison of 5 Brief Screening Tools for HAND in the USA and South Africa

Background: A screening test for HIV associated neurocognitive disorders (HAND) is urgently needed in busy HIV clinics. We compared the sensitivity and specificity of five brief screening tools for HAND and HIV-dementia. We hypothesised that the International HIV Dementia Scale (IHDS), the Montreal Cognitive Assessment (MOCA) and the Cognitive Assessment Tool-rapid version (CAT-rapid) would be…

Subtype Associations With HIV-Associated Neurocognitive Dysfunction

Background: Despite effective antiretroviral therapy, HIV–associated neurocognitive disorders (HAND) continue to be a problem. Many factors, including CD4 count and nadir, HIV viral load and HIV-1 subtype, have been associated with HAND. However, variability of the associations of these factors including subtype with HAND has not been evaluated in ethnically and culturally similar populations in…